Длина теломер лейкоцитов периферической крови как возможный прогностический маркер развития фибрилляции предсердий
Длина теломер лейкоцитов периферической крови как возможный прогностический маркер развития фибрилляции предсердий
Никулина С.Ю., Шишкова К.Ю., Шульман В.А. и др. Длина теломер лейкоцитов периферической крови как возможный прогностический маркер развития фибрилляции предсердий. CardioСоматика. 2020; 11 (2): 50–54.
DOI: 10.26442/22217185.2020.2.200227
DOI: 10.26442/22217185.2020.2.200227
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Фибрилляция предсердий (ФП) – одно из самых распространенных нарушений сердечного ритма. Важнейшим фактором риска его развития является пожилой возраст. Старение населения способствует росту распространенности данной патологии и возрастанию его социально-экономического бремени для общества в целом и больного в частности. Для адекватной терапии и профилактики ФП требуется поиск новых прогностических маркеров риска развития заболевания, его прогрессирования и ответа на терапию. Одним из таких маркеров является длина теломер – структур, расположенных на концах хромосом и защищающих их от деградации в процессе деления клетки. В статье представлен обзор мировых исследований, как подтверждающих, так и опровергающих роль длины теломер лейкоцитов с риском развития ФП.
Ключевые слова: фибрилляция предсердий, теломеры, длина теломер лейкоцитов, длина теломер миоцитов предсердия, радиочастотная катетерная аблация, клинические исследования, прогностические маркеры.
Key words: atrial fibrillation, telomers, length of telomers of leucocytes, length of telomers of myocytes of atrium, radiofrequency catheter ablation, clinical trials, predictive markers.
Ключевые слова: фибрилляция предсердий, теломеры, длина теломер лейкоцитов, длина теломер миоцитов предсердия, радиочастотная катетерная аблация, клинические исследования, прогностические маркеры.
________________________________________________
Key words: atrial fibrillation, telomers, length of telomers of leucocytes, length of telomers of myocytes of atrium, radiofrequency catheter ablation, clinical trials, predictive markers.
Список литературы
1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed) 2017; 70 (1): 50. DOI: 10.1016/j.rec.2016.11.033
2. Camm A, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429. DOI: 10.1093/eurheartj/ehq278
3. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8. DOI: 10.3410/M4-8
4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5 (2): 197–203. DOI: 10.2174/1566524053586545
5. Benetos A, Kark JD, Susser E et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging Cell 2013; 12 (4): 615–21. DOI: 10.1111/acel.12086
6. Bendix L, Thinggaard M, Fenger M et al. Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci 2014; 69 (2): 231–9. DOI: 10.1093/ gerona/glt153
7. Maximov VN, Malyutina SK, Orlov PS et al. Leukocyte Telomere Length as an Aging Marker and Risk Factor for Human Age-Related Diseases. Adv Gerontol 2017; 7 (2): 101–6. DOI: 10.1134/S2079057017020102
8. Roberts JD, Dewland TA, Longoria J et al. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol 2014; 7 (6): 1026–32. DOI: 10.1161/CIRCEP.114.001781
9. Staerk L, Wang B, Lunetta KL et al. Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. J Am Heart Assoc 2017; 6 (11): e006541. DOI: 10.1161/JAHA.117.006541
10. Siland JE, Geelhoed B, van Gelder IC et al. Telomere length and incident atrial fibrillation – data of the PREVEND cohort. PLoS One 2017; 12 (2): e0171545. DOI: 10.1371/journal.pone. 0171545
11. Carlquist JF, Knight S, Cawthon RM et al. Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm 2016; 13 (1): 21–7. DOI: 10.1016/j.hrthm.2015.07.032
12. Correction in the Article by Kirchhof et al. "2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS". Rev Esp Cardiol 2017; 70: 50.e1–e84. Rev Esp Cardiol (Engl Ed) 2017; 70 (11): 1031. DOI: 10.1016/j.rec.2017.07.009
13. Zhang N, Fan C, Gong M et al. Leucocyte telomere length and paroxysmal atrial fibrillation: A prospective cohort study and systematic review with meta-analysis. J Clin Lab Anal 2018; 32 (9): e22599. DOI: 10.1002/jcla.22599
14. Kaufman ES. Recurrent atrial fibrillation after ablation: Can telomere length identify patients who are young at heart? J Cardiovasc Electrophysiol 2019; 30 (7): 1125–6. DOI: 10.1111/jce.13960
15. Su C, Liu Z, Gao Y et al. Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2019; 30 (7): 1117–24. DOI: 10.1111/jce.13958
16. Pan KL, Hsiao YW, Lin YJ et al. Shorter Leukocyte Telomere Length Is Associated With Atrial Remodeling and Predicts Recurrence in Younger Patients With Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. Circ J 2019; 83 (7): 1449–55. DOI: 10.1253/circj.CJ-18-0880
17. Allende M, Molina E, Gonzalez-Porras JR et al. Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke 2016; 47 (3): 863–5. DOI: 10.1161/STROKEAHA.115.011837
2. Camm A, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429. DOI: 10.1093/eurheartj/ehq278
3. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8. DOI: 10.3410/M4-8
4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5 (2): 197–203. DOI: 10.2174/1566524053586545
5. Benetos A, Kark JD, Susser E et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging Cell 2013; 12 (4): 615–21. DOI: 10.1111/acel.12086
6. Bendix L, Thinggaard M, Fenger M et al. Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci 2014; 69 (2): 231–9. DOI: 10.1093/ gerona/glt153
7. Maximov VN, Malyutina SK, Orlov PS et al. Leukocyte Telomere Length as an Aging Marker and Risk Factor for Human Age-Related Diseases. Adv Gerontol 2017; 7 (2): 101–6. DOI: 10.1134/S2079057017020102
8. Roberts JD, Dewland TA, Longoria J et al. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol 2014; 7 (6): 1026–32. DOI: 10.1161/CIRCEP.114.001781
9. Staerk L, Wang B, Lunetta KL et al. Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. J Am Heart Assoc 2017; 6 (11): e006541. DOI: 10.1161/JAHA.117.006541
10. Siland JE, Geelhoed B, van Gelder IC et al. Telomere length and incident atrial fibrillation – data of the PREVEND cohort. PLoS One 2017; 12 (2): e0171545. DOI: 10.1371/journal.pone. 0171545
11. Carlquist JF, Knight S, Cawthon RM et al. Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm 2016; 13 (1): 21–7. DOI: 10.1016/j.hrthm.2015.07.032
12. Correction in the Article by Kirchhof et al. "2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS". Rev Esp Cardiol 2017; 70: 50.e1–e84. Rev Esp Cardiol (Engl Ed) 2017; 70 (11): 1031. DOI: 10.1016/j.rec.2017.07.009
13. Zhang N, Fan C, Gong M et al. Leucocyte telomere length and paroxysmal atrial fibrillation: A prospective cohort study and systematic review with meta-analysis. J Clin Lab Anal 2018; 32 (9): e22599. DOI: 10.1002/jcla.22599
14. Kaufman ES. Recurrent atrial fibrillation after ablation: Can telomere length identify patients who are young at heart? J Cardiovasc Electrophysiol 2019; 30 (7): 1125–6. DOI: 10.1111/jce.13960
15. Su C, Liu Z, Gao Y et al. Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2019; 30 (7): 1117–24. DOI: 10.1111/jce.13958
16. Pan KL, Hsiao YW, Lin YJ et al. Shorter Leukocyte Telomere Length Is Associated With Atrial Remodeling and Predicts Recurrence in Younger Patients With Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. Circ J 2019; 83 (7): 1449–55. DOI: 10.1253/circj.CJ-18-0880
17. Allende M, Molina E, Gonzalez-Porras JR et al. Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke 2016; 47 (3): 863–5. DOI: 10.1161/STROKEAHA.115.011837
2. Camm A, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429. DOI: 10.1093/eurheartj/ehq278
3. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8. DOI: 10.3410/M4-8
4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5 (2): 197–203. DOI: 10.2174/1566524053586545
5. Benetos A, Kark JD, Susser E et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging Cell 2013; 12 (4): 615–21. DOI: 10.1111/acel.12086
6. Bendix L, Thinggaard M, Fenger M et al. Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci 2014; 69 (2): 231–9. DOI: 10.1093/ gerona/glt153
7. Maximov VN, Malyutina SK, Orlov PS et al. Leukocyte Telomere Length as an Aging Marker and Risk Factor for Human Age-Related Diseases. Adv Gerontol 2017; 7 (2): 101–6. DOI: 10.1134/S2079057017020102
8. Roberts JD, Dewland TA, Longoria J et al. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol 2014; 7 (6): 1026–32. DOI: 10.1161/CIRCEP.114.001781
9. Staerk L, Wang B, Lunetta KL et al. Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. J Am Heart Assoc 2017; 6 (11): e006541. DOI: 10.1161/JAHA.117.006541
10. Siland JE, Geelhoed B, van Gelder IC et al. Telomere length and incident atrial fibrillation – data of the PREVEND cohort. PLoS One 2017; 12 (2): e0171545. DOI: 10.1371/journal.pone. 0171545
11. Carlquist JF, Knight S, Cawthon RM et al. Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm 2016; 13 (1): 21–7. DOI: 10.1016/j.hrthm.2015.07.032
12. Correction in the Article by Kirchhof et al. "2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS". Rev Esp Cardiol 2017; 70: 50.e1–e84. Rev Esp Cardiol (Engl Ed) 2017; 70 (11): 1031. DOI: 10.1016/j.rec.2017.07.009
13. Zhang N, Fan C, Gong M et al. Leucocyte telomere length and paroxysmal atrial fibrillation: A prospective cohort study and systematic review with meta-analysis. J Clin Lab Anal 2018; 32 (9): e22599. DOI: 10.1002/jcla.22599
14. Kaufman ES. Recurrent atrial fibrillation after ablation: Can telomere length identify patients who are young at heart? J Cardiovasc Electrophysiol 2019; 30 (7): 1125–6. DOI: 10.1111/jce.13960
15. Su C, Liu Z, Gao Y et al. Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2019; 30 (7): 1117–24. DOI: 10.1111/jce.13958
16. Pan KL, Hsiao YW, Lin YJ et al. Shorter Leukocyte Telomere Length Is Associated With Atrial Remodeling and Predicts Recurrence in Younger Patients With Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. Circ J 2019; 83 (7): 1449–55. DOI: 10.1253/circj.CJ-18-0880
17. Allende M, Molina E, Gonzalez-Porras JR et al. Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke 2016; 47 (3): 863–5. DOI: 10.1161/STROKEAHA.115.011837
________________________________________________
2. Camm A, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429. DOI: 10.1093/eurheartj/ehq278
3. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8. DOI: 10.3410/M4-8
4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5 (2): 197–203. DOI: 10.2174/1566524053586545
5. Benetos A, Kark JD, Susser E et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging Cell 2013; 12 (4): 615–21. DOI: 10.1111/acel.12086
6. Bendix L, Thinggaard M, Fenger M et al. Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci 2014; 69 (2): 231–9. DOI: 10.1093/ gerona/glt153
7. Maximov VN, Malyutina SK, Orlov PS et al. Leukocyte Telomere Length as an Aging Marker and Risk Factor for Human Age-Related Diseases. Adv Gerontol 2017; 7 (2): 101–6. DOI: 10.1134/S2079057017020102
8. Roberts JD, Dewland TA, Longoria J et al. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol 2014; 7 (6): 1026–32. DOI: 10.1161/CIRCEP.114.001781
9. Staerk L, Wang B, Lunetta KL et al. Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. J Am Heart Assoc 2017; 6 (11): e006541. DOI: 10.1161/JAHA.117.006541
10. Siland JE, Geelhoed B, van Gelder IC et al. Telomere length and incident atrial fibrillation – data of the PREVEND cohort. PLoS One 2017; 12 (2): e0171545. DOI: 10.1371/journal.pone. 0171545
11. Carlquist JF, Knight S, Cawthon RM et al. Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm 2016; 13 (1): 21–7. DOI: 10.1016/j.hrthm.2015.07.032
12. Correction in the Article by Kirchhof et al. "2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS". Rev Esp Cardiol 2017; 70: 50.e1–e84. Rev Esp Cardiol (Engl Ed) 2017; 70 (11): 1031. DOI: 10.1016/j.rec.2017.07.009
13. Zhang N, Fan C, Gong M et al. Leucocyte telomere length and paroxysmal atrial fibrillation: A prospective cohort study and systematic review with meta-analysis. J Clin Lab Anal 2018; 32 (9): e22599. DOI: 10.1002/jcla.22599
14. Kaufman ES. Recurrent atrial fibrillation after ablation: Can telomere length identify patients who are young at heart? J Cardiovasc Electrophysiol 2019; 30 (7): 1125–6. DOI: 10.1111/jce.13960
15. Su C, Liu Z, Gao Y et al. Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2019; 30 (7): 1117–24. DOI: 10.1111/jce.13958
16. Pan KL, Hsiao YW, Lin YJ et al. Shorter Leukocyte Telomere Length Is Associated With Atrial Remodeling and Predicts Recurrence in Younger Patients With Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. Circ J 2019; 83 (7): 1449–55. DOI: 10.1253/circj.CJ-18-0880
17. Allende M, Molina E, Gonzalez-Porras JR et al. Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke 2016; 47 (3): 863–5. DOI: 10.1161/STROKEAHA.115.011837
Авторы
С.Ю. Никулина*1, К.Ю. Шишкова1, В.А. Шульман1, А.А. Чернова1, В.Н. Максимов2
1 ФГБОУ ВО «Красноярский государственный медицинский университет
им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
2 Научно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН», Новосибирск, Россия
*nicoulina@mail.ru
1 Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
2 Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia
*nicoulina@mail.ru
1 ФГБОУ ВО «Красноярский государственный медицинский университет
им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
2 Научно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН», Новосибирск, Россия
*nicoulina@mail.ru
________________________________________________
1 Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
2 Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia
*nicoulina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.